Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
(COPD): A Meta-Analysis of METREX and METREO Patient-Reported
Outcomes, Response to Therapy and Lung Function

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function

Podrobná bibliografie
Hlavní autoři:	Chapman, K, Pavord, I, Paggiaro, P, Sciurba, F, Bafadhel, M, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S
Médium:	Conference item
Vydáno:	American Thoracic Society 2018

Podobné jednotky

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
Autor: Bafadhel, M, a další
Vydáno: (2018)

Mepolizumab for eosinophilic COPD
Autor: Sciurba, F, a další
Vydáno: (2018)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
Autor: Pavord, I, a další
Vydáno: (2017)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Autor: Pavord, I, a další
Vydáno: (2017)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
Autor: Gunsoy, N, a další
Vydáno: (2017)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
Autor: Shrimanker, R, a další
Vydáno: (2018)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
Autor: Mkorombindo T, a další
Vydáno: (2019-08-01)

Glucocorticoids and mepolizumab in eosinophilic asthma.
Autor: Bel, E, a další
Vydáno: (2014)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Autor: Steven W. Yancey, a další
Vydáno: (2019-09-01)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Autor: Bel, E, a další
Vydáno: (2014)

Mepolizumab in refractory eosinophilic asthma.
Autor: Pavord, I, a další
Vydáno: (2010)

Mepolizumab treatment in patients with severe eosinophilic asthma.
Autor: Ortega, H, a další
Vydáno: (2014)

Mepolizumab, quality of life, and severe eosinophilic asthma.
Autor: Pavord, I
Vydáno: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Autor: Ortega, H, a další
Vydáno: (2016)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
Autor: Yancey, S, a další
Vydáno: (2016)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Autor: Howell, I, a další
Vydáno: (2024)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Autor: Shrimanker, R, a další
Vydáno: (2017)

Eosinophils in COPD: just another biomarker?
Autor: Bafadhel, M, a další
Vydáno: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Autor: Imran Howell, a další
Vydáno: (2024-07-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
Autor: Terufumi Shimoda, a další
Vydáno: (2017-07-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
Autor: Shrimanker, R, a další
Vydáno: (2017)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
Autor: Ian D. Pavord, a další
Vydáno: (2022-05-01)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
Autor: Moran, AM, a další
Vydáno: (2020)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
Autor: Haldar, P, a další
Vydáno: (2009)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
Autor: Wechsler, M, a další
Vydáno: (2017)

Treatment of eosinophilic myositis with mepolizumab
Autor: Saadia Waheed, a další
Vydáno: (2018-01-01)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
Autor: Prazma CM, a další
Vydáno: (2021-06-01)

GLUCOLD, eosinophils and chronic obstructive pulmonary disease
Autor: Pavord, I
Vydáno: (2018)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
Autor: Mi-Kyeong Kim, a další
Vydáno: (2021-03-01)

Copd in the ed: eosinophils, treatment and outcomes, data from the pre-award study
Autor: Russell, R, a další
Vydáno: (2016)

Characterising non-eosinophilic COPD
Autor: Hambleton, K, a další
Vydáno: (2015)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
Autor: Menzella F, a další
Vydáno: (2016-06-01)

Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis.
Autor: Bafadhel, M, a další
Vydáno: (2014)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
Autor: Moran, A, a další
Vydáno: (2020)

Chronic obstructive pulmonary disease (COPD) and COPD-like phenotypes
Autor: Spyridon Fortis, a další
Vydáno: (2024-04-01)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
Autor: Frank C. Albers, a další
Vydáno: (2019-07-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
Autor: Chio Sakai, a další
Vydáno: (2024-07-01)

Investigating blood eosinophil count thresholds in patients with COPD
Autor: Russell, R, a další
Vydáno: (2018)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
Autor: Ravi Ranjan Pradhan, a další
Vydáno: (2019-01-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
Autor: Ryota Otoshi, a další
Vydáno: (2020-03-01)